The FINDER 1.5 Instrument helps hospitals, laboratories and other point-of-care settings meet the demand for fast and accurate testing. Credit: Baebies.

Baebies has obtained CE Mark for its Finder SARS-CoV-2 point-of-care test, which runs on the FINDER 1.5 Instrument.

The test performs RT-PCR testing for the detection of SARS-CoV-2.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It uses the company’s core digital microfluidics (DMF) technology to reduce the RT-PCR process.

Furthermore, the Finder SARS-CoV-2 test qualitatively detects RNA from the SARS-CoV-2 virus in nasopharyngeal as well as nasal swab samples and provides results in approximately 17 minutes.

Baebies stated that conventional RT-PCR testing results are typically reported after 24 hours.

The Finder SARS-CoV-2 testing platform features a toaster-sized, compact instrument with a mini-tablet for the user interface.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A single-use disposable cartridge is used to run each test.

Baebies co‑founder and CEO Richard West said: “CE Mark is an important regulatory milestone for Baebies to expand the reach of our Finder SARS-CoV-2 test and introduce the power of DMF to new markets across the world.

“Our technology unlocks access to rapid, accurate testing at the point of care, so communities can manage the threat of Covid-19 now and into the future.”

The company noted that the FINDER 1.5 Instrument uses DMF to quickly move discrete droplets by electrical control on the cartridge.

The device helps hospitals, laboratories and other point-of-care settings meet the demand for fast and accurate testing.

It delivers the accuracy of an RT-PCR lab test and the speed of a rapid antigen test.

Baebies has other panels that are currently under development. They will use the same cartridge format on the FINDER 1.5 platform.